Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
The New England Journal of Medicine|September 9, 2005
Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomasMichael Cullen, Neil Steven, Lucinda Billingham, et al.
Cancer Immunology, Immunotherapy : CII|May 20, 2008
Expression and function of T cell homing molecules in Hodgkin's lymphomaLee Machado, Ruth Jarrett, Susan Morgan, et al.
Cancer Chemotherapy and Pharmacology|February 21, 2013
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiationRuth Plummer, Paul Lorigan, Neil Steven, et al.
European Journal of Cancer (Oxford, England : 1990)|October 9, 2017
Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanomaTeresa M Petrella, Caroline Robert, Erika Richtig, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|December 1, 2021
Checkpoint Inhibition Reduces the Threshold for Drug-Specific T-Cell Priming and Increases the Incidence of Sulfasalazine HypersensitivitySean Hammond, Anna Olsson-Brown, Sophie Grice, et al.
Annals of Clinical and Translational Neurology|May 16, 2018
Seronegative antibody-mediated neurology after immune checkpoint inhibitorsRobert Wilson, David A Menassa, Alexander J Davies, et al.
European Journal of Cancer (Oxford, England : 1990)|August 24, 2020
Head and neck mucosal melanoma: The United Kingdom national guidelinesPablo Nenclares, Derfel Ap Dafydd, Izhar Bagwan, et al.
Head & Neck|August 28, 2021
What is the role of the surgeon in the management of head and neck mucosal melanoma in the immunotherapy era?Mark Edmond, Pablo Nenclares, Kevin Harrington, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2015
Clinical and biological effects of an agonist anti-CD40 antibody: a Cancer Research UK phase I studyPeter Johnson, Ruth Challis, Ferdousi Chowdhury, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2025
Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II StudyShailender Bhatia, Suzanne L Topalian, William Sharfman, et al.
Pageof 3